Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

2.

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E.

Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. Epub 2007 Jul 18.

3.

Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Findlow J, Taylor S, Aase A, Horton R, Heyderman R, Southern J, Andrews N, Barchha R, Harrison E, Lowe A, Boxer E, Heaton C, Balmer P, Kaczmarski E, Oster P, Gorringe A, Borrow R, Miller E.

Infect Immun. 2006 Aug;74(8):4557-65. Erratum in: Infect Immun. 2007 Aug;75(8):4187.

4.

Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Aaberge IS, Oster P, Helland OS, Kristoffersen AC, Ypma E, Høiby EA, Feiring B, Nøkleby H.

Clin Diagn Lab Immunol. 2005 May;12(5):599-605.

5.

Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

Gorringe AR, Taylor S, Brookes C, Matheson M, Finney M, Kerr M, Hudson M, Findlow J, Borrow R, Andrews N, Kafatos G, Evans CM, Read RC.

Clin Vaccine Immunol. 2009 Aug;16(8):1113-20. doi: 10.1128/CVI.00118-09. Epub 2009 Jun 24.

6.

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.

Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E.

Vaccine. 2003 Jan 30;21(7-8):734-7.

PMID:
12531351
7.

New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.

Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, Mulholland K, Martin D.

Pediatr Infect Dis J. 2007 Apr;26(4):345-50.

PMID:
17414400
8.

Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.

Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, Cuevas I, Carbonero M, Campa HC, Sierra G, Levin M.

Pediatr Infect Dis J. 2001 Nov;20(11):1054-61.

PMID:
11734711
9.

Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.

Hosking J, Rasanathan K, Mow FC, Jackson C, Martin D, O'Hallahan J, Oster P, Ypma E, Reid S, Aaberge I, Crengle S, Stewart J, Lennon D.

Clin Vaccine Immunol. 2007 Nov;14(11):1393-9. Epub 2007 Sep 26.

10.

Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E, Oster P, Martin D.

Clin Vaccine Immunol. 2007 Jul;14(7):830-8. Epub 2007 May 9.

11.

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators.

Lancet Infect Dis. 2012 Aug;12(8):597-607. Epub 2012 May 7.

PMID:
22569484
12.

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group.

Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Erratum in: Lancet. 2015 May 2;385(9979):1728.

PMID:
22260988
13.

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP.

Infect Immun. 2003 Apr;71(4):1650-5.

14.

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P.

Vaccine. 2007 Apr 20;25(16):3080-4. Epub 2007 Jan 22.

PMID:
17287053
15.

Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.

Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T.

Vaccine. 2015 Sep 22;33(39):5217-24. doi: 10.1016/j.vaccine.2015.06.103. Epub 2015 Jul 29.

PMID:
26232542
16.

A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.

Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE 3rd, Schmiel DH, Pinto V, Chen P, Zollinger WD.

Vaccine. 2010 Oct 8;28(43):6970-6. doi: 10.1016/j.vaccine.2010.08.048. Epub 2010 Aug 21.

PMID:
20732470
17.

Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.

McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon ER.

Pediatr Infect Dis J. 2002 Aug;21(8):747-53.

PMID:
12192163
18.

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD.

Vaccine. 2011 Feb 4;29(7):1413-20. doi: 10.1016/j.vaccine.2010.12.039. Epub 2011 Jan 1.

PMID:
21199704
19.

Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.

Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, O'Hallahan JM, Oster P, Mulholland K, Martin DR.

Pediatr Infect Dis J. 2009 May;28(5):385-90. doi: 10.1097/INF.0b013e318195205e.

PMID:
19384263
20.

Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.

Tejedor JC, Merino JM, Moro M, Navarro ML, Espín J, Omeñaca F, García-Sicilia J, Moreno-Pérez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N.

Pediatr Infect Dis J. 2012 Oct;31(10):1074-7.

PMID:
22828645

Supplemental Content

Support Center